Login
bluebird bio, Inc. NASDAQ: BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
| Name | bluebird bio, Inc. |
| Ticker | BLUE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 56.66 |
| 52W Low/High | 40.39 / 106.81 |
| Market cap | 3.2 B |
| 1Y Total Return |
-46.95%
Weak |
| 1Y Volatility |
66.64%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
Details
| Ticker | BLUE |
| Name | bluebird bio, Inc. |
| ISIN | US09609G1004 |
| CUSIP | 09609G100 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/18/20
| Close Price | 56.66 |
| 52W Low/High | 40.39 / 106.81 |
| Market cap | 3.2 B |
| 1Y Total Return |
-46.95%
Weak |
| 1Y Volatility |
66.64%
More Risk |
| Beta | 1.86 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -272.7% |
| Cash from Op. / Cur. Liabilities | -2.23 |
| Diluted Earnings / Share | -11.77 |
| ROE | - |
| ROIC | -59.1% |
| Price / Revenue | 14.3 |
| Price / Book | 2.0 |
| Price / CF | -7.8 |
| Current Ratio | 8.2 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.12 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
240
|
57
|
36
|
27
|
6
|
24
|
|
| Gross Profit |
235
|
55
|
35
|
26
|
6
|
24
|
|
| R&D |
624
|
506
|
366
|
240
|
150
|
105
|
|
| EBITDA |
-658
|
-669
|
-444
|
-280
|
-197
|
-106
|
|
| Operating Income |
-673
|
-678
|
-460
|
-286
|
-206
|
-111
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
60
|
55
|
50
|
41
|
37
|
33
|
|
| EPS exc. Extra |
-11.77
|
-12.00
|
-9.52
|
-7.36
|
-5.58
|
-3.63
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
2,108
|
2,023
|
1,762
|
1,457
|
942
|
999
|
|
| Cash, Eq & Invt ShortTerm |
1,549
|
1,254
|
1,077
|
1,095
|
576
|
811
|
|
| Total Current Assets |
1,613
|
1,301
|
1,106
|
1,119
|
583
|
815
|
|
| Total Non-Current Assets |
494
|
723
|
656
|
339
|
359
|
184
|
|
| Intangibles |
25
|
30
|
28
|
32
|
36
|
39
|
|
| Total Liabilities |
426
|
387
|
304
|
257
|
182
|
80
|
|
| Total Current Liabilities |
197
|
162
|
116
|
78
|
40
|
28
|
|
| Long Term Debt |
229
|
225
|
188
|
179
|
142
|
52
|
|
| Shareholder equity |
1,682
|
1,636
|
1,458
|
1,200
|
759
|
919
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-439
|
-496
|
-361
|
-237
|
-143
|
-73
|
|
| Depreciation |
19
|
17
|
15
|
11
|
9
|
7
|
|
| Cash from Investing |
806
|
-192
|
-663
|
-18
|
-231
|
-349
|
|
| Capex |
49
|
73
|
43
|
61
|
11
|
7
|
|
| Cash from Financing |
550
|
676
|
671
|
724
|
3
|
839
|
|
| Stock Issued |
550
|
676
|
669
|
686
|
6
|
839
|
|
| Debt (LT) Issued |
0
|
-1
|
-1
|
0
|
0
|
0
|
|
| Free Cash Flow |
-89
|
-946
|
-790
|
-364
|
-327
|
-342
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
8.2
|
8.0
|
9.5
|
14.4
|
14.4
|
29.1
|
|
| Financial Leverage D/E |
0.12
|
0.12
|
0.11
|
0.13
|
0.11
|
0.00
|
|
| Return on Capital Avg |
-59.1%
|
-47.4%
|
-45.9%
|
-42.4%
|
-38.8%
|
-56.1%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available